LncRNA SNHG۱۱,A Novel biomarker of resistance glioblastoma

Glioblastoma (GBM) is the most prevalent and aggressive type of tumor in the central nervous system, accounting for approximately ۸۰% of all cases. It is recognized for its highly invasive nature and poor prognosis, making it one of the most challenging forms of brain cancer to treat. The incidence rate of glioblastoma is estimated to be around ۳ to ۴ cases per ۱۰۰,۰۰۰ individuals. One of the main factors contributing to its poor prognosis is its resistance to standard chemotherapy treatments, particularly temozolomide (TMZ), which is widely used as a first-line treatment. Despite its initial efficacy, many GBM cases develop resistance to TMZ, leading to tumor recurrence and treatment failure. Understanding the mechanisms behind this resistance is therefore of critical importance for the development of more effective therapies. In recent years, long non-coding RNAs (LncRNAs) have gained attention due to their emerging roles in cancer biology. These non-coding RNAs have been implicated in various processes related to tumor progression, including proliferation, invasion, and metastasis. Among them, SNHG۱۱ has been identified as a potential contributor to the progression of glioblastoma. However, its specific role in mediating resistance to TMZ has not been fully elucidated. This study aims to explore the function of SNHG۱۱ in the context of TMZ-resistant glioblastoma, with the goal of identifying new therapeutic targets to overcome chemotherapy resistance. To investigate the role of SNHG۱۱, a TMZ-resistant GBM cell line was established by gradually increasing the concentration of TMZ (ranging from ۱ µM to ۲۰۰ µM) over time. The development of resistance was confirmed through MTT assays, which assessed cell viability in response to TMZ treatment (P-value = ۰.۰۰۱۱). Furthermore, the expression levels of SNHG۱۱ were measured using quantitative reverse transcription PCR (qRT-PCR). The findings revealed that SNHG۱۱ expression was significantly elevated in TMZ-resistant GBM cells compared to non-resistant cells (P-value = ۰.۰۰۹۱). These results suggest that SNHG۱۱ plays a crucial role in the development of resistance to TMZ in glioblastoma. Given that SNHG۱۱ has already been implicated in GBM progression, its involvement in chemotherapy resistance further underscores its potential as a therapeutic target. The outcomes of this research indicate that targeting lncRNA SNHG۱۱ may provide a novel and promising approach to overcoming drug resistance in GBM, offering new avenues for improving patient outcomes in this aggressive form of cancer.

کلیدواژه ها:

Glioblastoma ، LncRNA SNHG ۱۱ ، Resistance ، Temozolomide